Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation - possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection
J. Rosenau et al., Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation - possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection, J HEPATOL, 34(6), 2001, pp. 895-902
Background/Aims: Reinfection with hepatitis B virus (HBV) after liver trans
plantation (OLT) is associated with an unfavourable clinical course. Lamivu
dine/hepatitis B immune globulin (HBIG) combination treatment reduces reinf
ection rates. However, it is unclear at what time point lamivudine should b
e started and which HBIG doses are sufficient.
Methods: Twenty-one patients receiving combination treatment,were studied.
Lamivudine was started up to 16.5 months before OLT and continued thereafte
r. HBIG was started intraoperatively and continued according to anti-HBs-ti
ters. Median follow-up after OLT was 20 months.
Results: Eleven patients received lamivudine pretreatment for >2 (median 6)
months due to initial HBV-DNA-positivity (median 749 pg/ml), After initial
lamivudine response HBV-DNA increased in two of them to concentrations abo
ve 10 pg/ml prior to OLT. Both had developed mutations in the YMDD motif an
d suffered from HBV reinfection 13 and 75 days postoperatively, Individual
HBIG consumption was highly variable (range 787-4766 IU/month). Twenty-two
percent of anti-HBs titers measured before HBIG administration were below 1
00 IU/I.
Conclusion: Combined reinfection prophylaxis with lamivudine and HBIG is ef
fective in patients with controlled viral replication at the time of OLT, H
owever, pretransplantation lamivudine resistance is a risk factor for reinf
ection. Low dose HBIG maintenance therapy individualized according to anti-
HBs-titers appears to be tenable. (C) 2001 European Association for the Stu
dy of the Liver. Published by Elsevier Science B.V. All rights reserved.